Commitments and Contingencies—Litigation,” to our consolidated financial statements.
We expect that this increase in selling, general and administrative expense will be offset somewhat by the moratorium of the medical device tax in the U. S.  for the next two calendar years beginning in January 2016.
Income Tax Provision We recorded an income tax provision of $27.7 million for fiscal 2016, compared to an income tax benefit of $84.9 million for fiscal 2015.
The increase in income tax provision for fiscal 2016 was due to the fact that we had a full valuation allowance on most of our federal, state and certain foreign deferred tax assets prior to March 31, 2015, at which time most of the valuation allowance was reversed.
The income tax provision for fiscal 2016 was primarily due to the income before taxes of $65.8 million generated in fiscal 2016, primarily in the U. S.  and Germany.
The income tax benefit in fiscal 2015 was comprised of an $87.1 million deferred tax benefit primarily due to the release of our valuation allowance on certain of our deferred tax assets in the year ended March 31, 2015, partially offset by a current income tax provision of $2.2 million in U.
S and Germany.
Net Income For fiscal 2016, we recognized net income of $38.1 million, or $0.90 per basic share and $0.85 per diluted share, compared to $113.7 million, or $2.80 per basic share and $2.65 per diluted share for fiscal 2015.
Our net income for fiscal 2016 was driven primarily to higher Impella product revenue due to greater utilization of our Impella products in the U. S.  and Europe, partially offset by the increase in income tax provision for fiscal 2016 due to the fact that we had a full valuation allowance on most of our deferred tax assets prior to March 31, 2015, at which time most of the valuation allowance was reversed.
Our net income for fiscal 2015 included an income tax benefit of $84.9 million, primarily due to the release of our valuation allowance on certain of our deferred tax assets.
Fiscal Years Ended March 31, 2015 and March 31, 2014 (“fiscal 2015” and “fiscal 2014”) Revenue Our revenue is comprised of the following:
## Table 0 ##
Impella product revenue encompasses Impella 2.5, Impella CP, Impella 5.0, Impella LD and Impella RP product sales.
Service and other revenue represents revenue earned on service maintenance contracts and preventive maintenance calls.
Other product revenue includes AB5000 and product accessory revenue.
Total revenue for fiscal 2015 increased by $46.7 million, or 25%, to $230.3 million from $183.6 million for fiscal 2014.
The increase in total revenue was primarily due to higher Impella revenue due mainly to greater utilization of our products in the U. S.  Impella product revenue for fiscal 2015 increased by $45.7 million, or 27%, to $212.7 million from $167.0 million for fiscal 2014.
Most of our increase in Impella revenue was from disposable catheter sales in the U. S. , as we focus on increasing utilization of our disposable catheter products through continued investment in our field organization and physician training programs.
Service and other revenue for fiscal 2015 increased by $2.9 million, or 27%, to $13.8 million from $10.9 million for fiscal 2014.
The increase in service revenue was primarily due to an increase in preventative maintenance service contracts, as we expand the use of our Impella AIC consoles to additional sites.
Other product revenue for fiscal 2015 decreased by $1.9 million, or 35%, to $3.5 million from $5.4 million for fiscal 2014.
The decrease in other revenue was due to a decline in AB5000 disposable sales.
We also had no sales of BVS 5000 in fiscal 2015 and we are no longer actively producing or selling that product.
The Company’s operations in Malaysia currently operate under a tax holiday, which will expire in 2018.
This tax holiday may be extended if specific conditions are met.
The net impact of the tax holiday was to decrease the Company’s net loss by $1 million in 2013, less than $.01 per share, diluted.
The net impact of tax holidays decreased the Company’s net loss by $11 million in 2012, less than $.02 per share, diluted, and increased the Company’s net income by $9 million in 2011, less than $.01 per share, diluted.
A reconciliation of the gross unrecognized tax benefits is as follows:
## Table 1 ##
The amount of unrecognized tax benefits that would impact the effective tax rate was $3 million, $2 million, and $4 million as of December 28, 2013, December 29, 2012 and December 31, 2011, respectively.
The Company had no accrued interest related to unrecognized tax benefits as of December 28, 2013 and accrued interest related to unrecognized tax benefits of $2 million as of December 29, 2012 and December 31, 2011.
The Company had no accrued penalties related to unrecognized tax benefits as of December 28, 2013, December 29, 2012 and December 31, 2011.
The Company recognizes potential accrued interest and penalties to unrecognized tax benefits as interest expense and income tax expense, respectively.
The Company recorded a reduction of interest expense of $2 million and no charge related to penalty expense in its consolidated statement of operations in 2013.
The Company had no charge related to interest expense or penalty expense in its consolidated statement of operations in 2012.
The Company recorded a reduction of interest expense of $2 million and a decrease of $1 million of penalty expense in its consolidated statement of operations in 2011.
During the 12 months beginning December 29, 2013, the Company expects to reduce its unrecognized tax benefits by $31 million primarily as a result of the settlement of tax audits with certain foreign tax authorities.
The Company does not believe it is reasonably possible that other unrecognized tax benefits will materially change in the next 12 months.
However, the resolutions and/or closure of open audits are highly uncertain.
As of December 25, 2010, the Canada Revenue Agency, or CRA, had completed its audit of ATI for the years 2000 through 2004 and issued its final Notice of Assessment.
The CRA is currently auditing international transactions for the years 2005 through 2010.
During the second quarter of 2010 the U. S.  Internal Revenue Service completed its audit of the U. S.  Federal income tax returns for the years ending 2004 through 2006 inclusive.
As of December 31, 2011 the German tax authorities completed their audit of the Company’s former German subsidiaries for the tax years 2004 through 2007.
The German tax authorities conducted an audit for the tax years 2008 through 2011 in 2013.
The Company is not currently aware of any adjustments as a result of this audit.
The Company and its subsidiaries have several foreign, foreign provincial, and U. S.  state audits in process at any one point in time.
The Company has provided for uncertain tax positions that require a liability under the adopted method to account for uncertainty in income taxes.
The Company has not recognized any current or long-term deferred tax assets under a valuation allowance as a result of the application of uncertainty in income taxes in ASC 740 for unrecognized tax benefits as of December 28, 2013.
Commission and brokerage increased 7.8% to $311.0 million in 2011 compared to $288.4 million in 2010.
This variance was principally due to an increase in premiums earned.
Segment other underwriting expenses decreased slightly to $27.3 million in 2011 compared to $27.6 million in 2010.
Bermuda.
The following table presents the underwriting results and ratios for the Bermuda segment for the periods indicated.
## Table 2 ##
Premiums.
Gross written premiums increased 1.3% to $734.4 million in 2012 compared to $725.3 million in 2011, primarily due to continued growth of new business and increased premium on existing business written in our Bermuda office, partially offset by lower premiums from our European operations due to combined competitive conditions and a negative $14.7 million impact from movement in foreign exchange rates.
Net written premiums increased 1.1% to $733.8 million in 2012 compared to $725.5 million in 2011, in line with the increase in gross written premiums.
Premiums earned decreased 5.8% to $680.9 million in 2012 compared to $723.0 million in 2011.
The change in premiums earned relative to net written premiums is the result of timing; premiums are earned ratably over the coverage period whereas written premiums are recorded at the initiation of the coverage period.
Gross written premiums decreased 1.1% to $725.3 million in 2011 compared to $733.0 million in 2010, primarily due to reduced participations and non-renewal of U. K.  property business, where rate increases were not achieved, partially offset by an increase of $11.3 million in reinstatement premiums due to higher catastrophe loss activity in the current period and a $16.0 million favorable foreign exchange impact.
Net written premiums decreased 1.0% to $725.5 million for in 2011 compared to $733.0 million in 2010, in line with the decrease in gross written premiums.
Premiums earned decreased 2.1% to $723.0 million in 2011 compared to $738.4 million in 2010.
The change in premiums earned is in line with the decline in net written premiums.
Performance Graph The following graph is a comparison of the five-year cumulative return of our common shares, the Standard & Poor’s 500 Index (the “S&P 500 Index”) and the National Association of Real Estate Investment Trusts’ (“NAREIT”) All Equity Index (excluding health care real estate investment trusts), a peer group index.
The graph assumes that $100 was invested on December 31, 2005 in our common shares, the S&P 500 Index and the NAREIT All Equity Index and that all dividends were reinvested without the payment of any commissions.
There can be no assurance that the performance of our shares will continue in line with the same or similar trends depicted in the graph below.

<table><tr><td></td><td></td><td colspan="2">Fiscal Years Ended March 31,</td></tr><tr><td></td><td></td><td>2015</td><td>2014</td></tr><tr><td></td><td></td><td colspan="2">(in $000's)</td></tr><tr><td>Impella product revenue</td><td>$</td><td>212,665</td><td>$166,971</td></tr><tr><td>Service and other revenue</td><td></td><td>13,768</td><td>10,944</td></tr><tr><td>Other products</td><td></td><td>3,517</td><td>5,365</td></tr><tr><td>Total product revenue</td><td></td><td>229,950</td><td>183,280</td></tr><tr><td>Funded research and development</td><td></td><td>361</td><td>363</td></tr><tr><td>Total revenue</td><td>$</td><td>230,311</td><td>$183,643</td></tr></table>
<table><tr><td></td><td>2013</td><td>2012</td><td>2011</td></tr><tr><td></td><td colspan="3">(In millions)</td></tr><tr><td>Balance at beginning of year</td><td>$56</td><td>$69</td><td>$42</td></tr><tr><td>Increases for tax positions taken in prior years</td><td>1</td><td>3</td><td>28</td></tr><tr><td>Decreases for tax positions taken in prior years</td><td>-2</td><td>-4</td><td>-4</td></tr><tr><td>Increases for tax positions taken in the current year</td><td>4</td><td>3</td><td>8</td></tr><tr><td>Decreases for settlements with taxing authorities</td><td>-7</td><td>-15</td><td>-5</td></tr><tr><td>Balance at end of year</td><td>$52</td><td>$56</td><td>$69</td></tr></table>
<table><tr><td></td><td colspan="3">Years Ended December 31,</td><td colspan="2">2012/2011</td><td colspan="2">2011/2010</td></tr><tr><td>(Dollars in millions)</td><td>2012</td><td>2011</td><td>2010</td><td>Variance</td><td>% Change</td><td>Variance</td><td>% Change</td></tr><tr><td>Gross written premiums</td><td>$734.4</td><td>$725.3</td><td>$733.0</td><td>$9.1</td><td>1.3%</td><td>$-7.7</td><td>-1.1%</td></tr><tr><td>Net written premiums</td><td>733.8</td><td>725.5</td><td>733.0</td><td>8.2</td><td>1.1%</td><td>-7.5</td><td>-1.0%</td></tr><tr><td>Premiums earned</td><td>$680.9</td><td>$723.0</td><td>$738.4</td><td>$-42.0</td><td>-5.8%</td><td>$-15.5</td><td>-2.1%</td></tr><tr><td>Incurred losses and LAE</td><td>408.2</td><td>613.9</td><td>457.9</td><td>-205.6</td><td>-33.5%</td><td>155.9</td><td>34.0%</td></tr><tr><td>Commission and brokerage</td><td>184.4</td><td>174.0</td><td>171.1</td><td>10.3</td><td>5.9%</td><td>2.9</td><td>1.7%</td></tr><tr><td>Other underwriting expenses</td><td>30.6</td><td>26.3</td><td>26.4</td><td>4.3</td><td>16.4%</td><td>-0.1</td><td>-0.5%</td></tr><tr><td>Underwriting gain (loss)</td><td>$57.8</td><td>$-91.2</td><td>$83.0</td><td>$149.0</td><td>-163.3%</td><td>$-174.2</td><td>-209.9%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Point Chg</td><td></td><td>Point Chg</td></tr><tr><td>Loss ratio</td><td>60.0%</td><td>84.9%</td><td>62.0%</td><td></td><td>-24.9</td><td></td><td>22.9</td></tr><tr><td>Commission and brokerage ratio</td><td>27.1%</td><td>24.1%</td><td>23.2%</td><td></td><td>3.0</td><td></td><td>0.9</td></tr><tr><td>Other underwriting expense ratio</td><td>4.4%</td><td>3.6%</td><td>3.6%</td><td></td><td>0.8</td><td></td><td>-</td></tr><tr><td>Combined ratio</td><td>91.5%</td><td>112.6%</td><td>88.8%</td><td></td><td>-21.1</td><td></td><td>23.8</td></tr><tr><td colspan="2">(Some amounts may not reconcile due to rounding.)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>

Question: In the year with largest amount of Gross written premiums, what's the increasing rate of Other underwriting expenses?
Answer: 0.14052